Retro Bio’s $1.8b moment: Hopes up as Alzheimer’s trial advances (opens in new tab)

Sam Altman-backed longevity startup moves deeper into human testing as investors bet big on the future of healthier aging. Aging used to be something medicine reacted to. Now, a growing number of biotech companies want to treat it before the damage fully arrives. Retro Biosciences, the longevity startup backed by OpenAI CEO Sam Altman, has […] The post appeared first on <a href="